医学
伊立替康
福克斯
奥沙利铂
福尔菲里
内科学
结直肠癌
肿瘤科
养生
回顾性队列研究
病历
癌症
作者
Rui‐Hua Xu,Wei Wang,Bo Zhu,Xiaoyan Lin,Ding Ma,Lingjun Zhu,Qingchuan Zhao,Yongzhan Nie,Xiujun Cai,Qi Li,Weijia Fang,Hongyan Li,Ning Wang,Yun Chen,Cike Peng,Honghao Fang,Lin Shen
出处
期刊:BMC Cancer
[Springer Nature]
日期:2020-02-18
卷期号:20 (1)
被引量:25
标识
DOI:10.1186/s12885-020-6557-5
摘要
Colorectal cancer (CRC) is the third most prevalent cancer in China but few large-scale studies were conducted to understand CRC patients. The current study is aimed to gain a real-world perspectives of CRC patients in China.Using electronic medical records of sampled patients between 2011 and 2016 from 12 hospitals in China, a retrospective cohort study was conducted to describe demographics and disease prognosis of CRC patients, and examine treatment sequences among metastatic CRC (mCRC) patients. Descriptive, comparative and survival analyses were conducted.Among mCRC patients (3878/8136, 48%), the fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and other oxaliplatin-based regimens were the most widely-used first-line treatment (42%). Fluorouracil, leucovorin, irinotecan (FOLFIRI) and other irinotecan-based regimens dominated the second-line (40%). There was no a dominated regimen for the third-line. The proportion of patients receiving chemotherapy with targeted biologics increased from less than 20% for the first- and second- lines to 34% for the third-line (p < 0.001). The most common sequence from first- to second-line was from FOLFOX and other oxaliplatin-based regimens to FOLFIRI and other irinotecan-based regimens (286/1200, 24%).Our findings reflected a lack of consensus on the choice of third-line therapy and limited available options in China. It is evident o continue promoting early CRC diagnosis and to increase the accessibility of treatment options for mCRC patients. As the only nationwide large-scale study among CRC and mCRC patients before more biologics became available in China, our results can also be used as the baseline to assess treatment pattern changes before and after more third-line treatment were approved and covered into the National Health Insurance Plan in China between 2017 and 2018.
科研通智能强力驱动
Strongly Powered by AbleSci AI